Fragrance or foolery: 15 big drug events will resolve before April
This article was originally published in Scrip
Executive Summary
There are 15 big drug development decisions to be taken before April 1, seven of those in the hands of regulatory agencies in the US and Europe. The rest are dependent on clinical data, and some of the companies involved almost certainly already know which way the results going. All of which leaves 14 companies' senior management teams (Sanofi's has two clinical trials to ponder) wondering whether they will feel like bunches of April flowers, or bunches of fools.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.